Issue link: https://www.e-digitaleditions.com/i/1420307
30 BioPharm International eBook October 2021 www.biopharminternational.com Industry Organizations Assist Pharma During the Pandemic and Beyond BioPharm International checked in with AAPS, IPEC-Americas, and PDA to get an update on how the organizations are navigating the pandemic and planning for the future. P harmaceutical development, manufacturing, and quality efforts are often advanced by the work of industry associations and members through confer- ences, training sessions, publications, and working groups. These efforts continued during the past 18 months, despite restrictions posed by the COVID-19 pan- demic. The American Association of Pharmaceutical Scientists (AAPS), the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas), and the Parenteral Drug Association (PDA) shared recent activities and industry contri- butions with BioPharm International. AAPS SCIENCE-DRIVEN ACTIVITIES W hile the pandemic postponed many in-person meet- i ng s for pha r maceut ic a l sc ient ists , A A P S l au nc hed strategies to promote virtual discussion of scientif ic top- ics, supported pandemic research efforts through pub- l ications, and planned for in-person col laboration in 2022. A APS Executive Director Tina S. Morris, PhD, prov ided a n update on sc ience-d r iven ac t iv it ies a nd organizational plans to BioPharm International. BioPharm: W hat initiatives did A A PS develop in 2021? Morris (AAPS): A APS continued to lead with sci- ence in 2021, and to pivot to add itiona l tactics that br ing scient ists toget her to sha re t heir resea rch and i n si ght . T he or g a n i z at ion r e l au nc he d it s Nat ion a l Biote c h nolog y C on ferenc e ( N BC) a nd w i l l de l iv er PharmSci 360 in October in a hybrid format, which will allow scientists from around the world to engage online THE EDITORS OF BIOPHARM INTERNATIONAL Regulatory Sourcebook Industry Perspectives LEOWOLFERT - STOCK.ADOBE.COM